Carbon Footprint of Diagnostic Modalities Used in Inflammatory Bowel Disease Care: The EVERGREEN ‐ IBD Study (EVERGREEN‐IBD: Evaluating Value, Emissions, Resource Use, and GREEN diagnostics in IBD)

ABSTRACT Background Healthcare contributes 4.4%–5% of global greenhouse gas emissions. Inflammatory bowel disease (IBD) requires repeated diagnostic investigations throughout a patient's lifetime, adding to healthcare's environmental footprint. However, the carbon footprint and cost of IBD diagnostic modalities have not been systematically compared Aims To quantify per‐procedure emissions and relative costs of IBD diagnostics and model potential savings from intestinal ultrasound (IUS) when clinically appropriate. Methods This prospective observational study quantified operational emissions at AIG Hospitals, Hyderabad, India, during December 2025 using the Greenhouse Gas Protocol, institutional data, and a three‐state power model. Procedures included laboratory tests (27,330), colonoscopy/enteroscopy (1290), CT (1520), MRI (589), and IUS (923). Sensitivity analyses were performed to assess the robustness of emission estimates by varying assumptions regarding infrastructure allocation, equipment power consumption, procedure volumes, and electricity grid emission factors. Results Emissions ranged from 0.462 kg CO 2 e per laboratory test to 21.25 kg CO 2 e per MRI. IUS (0.850 kg CO 2 e) was the lowest‐carbon imaging modality, with 4.6‐, 6.8‐, and 25.0‐fold lower emissions than colonoscopy/enteroscopy, CT, and MRI, respectively. Cross‐sectional imaging contributed 53.7% of total emissions (39,778 kg CO 2 e), versus 2.0% for IUS. Costs increased with emissions. When clinically appropriate, substituting IUS for colonoscopy or MR enterography could reduce per‐procedure emissions by 78.0% and 96.0%, respectively. Conclusions Carbon emissions and cost rise together across IBD diagnostics; when clinically appropriate, IUS is the lowest‐carbon, lowest‐cost imaging modality. Patient‐level studies are needed to confirm modelled savings. Trial Registration ClinicalTrials.gov NCT07431983

Authors

Institutions

Publication Details

Journal
Alimentary Pharmacology & Therapeutics
Published
2026-11-13
DOI
https://doi.org/10.1111/apt.71091
Primary Topic
Environmental Impact and Sustainability
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Carbon Footprint of Diagnostic Modalities Used in Inflammatory Bowel Disease Care: The EVERGREEN ‐ IBD Study (EVERGREEN‐IBD: Evaluating Value, Emissions, Resource Use, and GREEN diagnostics in IBD)

Rajendra Patel, Rupa Banerjee, D. Nageshwar Reddy, Hardik Rughwani et al.
8 links
Alimentary Pharmacology & Therapeutics
Environmental Impact and Sustainability
article

Carbon Footprint of Diagnostic Modalities Used in Inflammatory Bowel Disease Care: The EVERGREEN ‐ IBD Study (EVERGREEN‐IBD: Evaluating Value, Emissions, Resource Use, and GREEN diagnostics in IBD)

Rajendra Patel, Rupa Banerjee, D. Nageshwar Reddy, Hardik Rughwani, Harshini Reddy
article en

Abstract

ABSTRACT Background Healthcare contributes 4.4%–5% of global greenhouse gas emissions. Inflammatory bowel disease (IBD) requires repeated diagnostic investigations throughout a patient's lifetime, adding to healthcare's environmental footprint. However, the carbon footprint and cost of IBD diagnostic modalities have not been systematically compared Aims To quantify per‐procedure emissions and relative costs of IBD diagnostics and model potential savings from intestinal ultrasound (IUS) when clinically appropriate. Methods This prospective observational study quantified operational emissions at AIG Hospitals, Hyderabad, India, during December 2025 using the Greenhouse Gas Protocol, institutional data, and a three‐state power model. Procedures included laboratory tests (27,330), colonoscopy/enteroscopy (1290), CT (1520), MRI (589), and IUS (923). Sensitivity analyses were performed to assess the robustness of emission estimates by varying assumptions regarding infrastructure allocation, equipment power consumption, procedure volumes, and electricity grid emission factors. Results Emissions ranged from 0.462 kg CO 2 e per laboratory test to 21.25 kg CO 2 e per MRI. IUS (0.850 kg CO 2 e) was the lowest‐carbon imaging modality, with 4.6‐, 6.8‐, and 25.0‐fold lower emissions than colonoscopy/enteroscopy, CT, and MRI, respectively. Cross‐sectional imaging contributed 53.7% of total emissions (39,778 kg CO 2 e), versus 2.0% for IUS. Costs increased with emissions. When clinically appropriate, substituting IUS for colonoscopy or MR enterography could reduce per‐procedure emissions by 78.0% and 96.0%, respectively. Conclusions Carbon emissions and cost rise together across IBD diagnostics; when clinically appropriate, IUS is the lowest‐carbon, lowest‐cost imaging modality. Patient‐level studies are needed to confirm modelled savings. Trial Registration ClinicalTrials.gov NCT07431983

Alimentary Pharmacology & Therapeutics
Asian Institute of Gastroenterology (IN)
Good health and well-being, Climate action
Environmental Impact and Sustainability
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon